Lessons From Synergy Pharmaceuticals Stock's Disastrous Fall
supplements April 5th. 2019, 9:22pmSynergy Pharmaceuticals (NASDAQ: SGYP) beat the odds by successfully winning FDA approval of Trulance last year, but it may not matter. Recently, management warned its struggling to renegotiate its debt and that increases the risk of its bankruptcy.
In this clip from The Motley Fool’s Industry Focus: Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss what’s going on and more importantly, lessons biotech investors can learn to spot high-risk companies like this in the future.
————————————————————————
Subscribe to The Motley Fool’s YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
Tweets by themotleyfool
Video Rating: / 5
Email This Post
Compensation Disclosure
-
This site receives compensation for referred sales of some or all mentioned products.
